Omid Hamid on Vigilance with Toxicities from Combination Immunotherapies

Omid Hamid, MD, chief of Translational Research and Immunotherapy of The Angeles Clinic, discusses some toxicities that come from combination immunotherapies, such as type 1 diabetes and hypoadrenalism.

Despite the ease with which these adverse events can usually be remedied, Hamid urges clinicians to carefully consider a patient’s complaints. If these toxicities are caught early enough, they are less complicated to deal with.